Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies. Vey N, Salamero O, Bajel A, Montesinos P, et al. Leuk Lymphoma 2026;67:2305-2312.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Vey N, Salamero O, Bajel A, Montesinos P, et al. Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies. Leuk Lymphoma 2026;67:2305-2312.
PMID: 42503467